Management of sagittal craniosynostosis: morphological comparison of eight surgical techniques

The aim of this study was to carry out a retrospective multicentre study comparing the morphological outcome of 8 techniques used for the management of sagittal synostosis versus a large cohort of control patients. Computed tomographic (CT) images were obtained from children CT-scanned for non-craniosynostosis related events (n = 241) and SS patients at preoperative and postoperative follow-up stages (n = 101). No significant difference in morphological outcomes was observed between the techniques considered in this study. However, the majority of techniques showed a tendency for relapse. Further, the more invasive procedures at older ages seem to lead to larger intracranial volume compared to less invasive techniques at younger ages. This study can be a first step towards future multicentre studies, comparing surgical results and offering a possibility for objective benchmarking of outcomes between methods and centres.     

“中国科技期刊卓越行动计划”领军期刊与对标期刊的指标特征分析与发展建议

【目的】 通过比较2019年获得“中国科技期刊卓越行动计划”领军期刊项目资助的期刊(以下简称“领军期刊”)与其对标期刊,探索我国科技期刊缩小与世界顶级期刊差距的对策,为我国一流科技期刊建设提供参考和借鉴。【方法】 利用Web of Science (WoS) 数据库和期刊官网,检索并总结领军期刊与其对标期刊的各项指标数据,分析领军期刊最近5年来的发展情况。【结果】 22种领军期刊的主要指标数据明显上升。2020年领军期刊共发表Article 和Review文章4025篇,比2019年的2630篇增长53.0%,2020年刊均载文量为183篇,比2019年的120篇增长53.0%;领军期刊总被引频次由2019年的99767 次大幅增长至2020年的153610次,增幅达54.0%;2020年领军期刊的平均被引半衰期为3.73年,而对标期刊的平均被引半衰期为9.35年。2020年,16种领军期刊跻身JCR学科排名前10%,10种领军期刊跻身JCR学科排名前5%。【结论】 领军期刊应构建良性的期刊发展生态、动态调整期刊的发展目标、紧扣国家战略和重大需求布局期刊发展方向、重视人才发展与储备、构建自主可控的国际传播平台与渠道,以完成引领行业发展的使命任务,实现可持续发展,从而带动我国期刊行业的整体发展与进步。     

Preferential responses to faces in superior temporal and medial prefrontal cortex in three-year-old children

Perceiving faces and understanding emotions are key components of human social cognition. Prior research with adults and infants suggests that these social cognitive functions are supported by superior temporal cortex (STC) and medial prefrontal cortex (MPFC). We used functional near-infrared spectroscopy (fNIRS) to characterize functional responses in these cortical regions to faces in early childhood. Three-year-old children (n = 88, M(SD) = 3.15(.16) years) passively viewed faces that varied in emotional content and valence (happy, angry, fearful, neutral) and, for fearful and angry faces, intensity (100%, 40%), while undergoing fNIRS. Bilateral STC and MPFC showed greater oxygenated hemoglobin concentration values to all faces relative to objects. MPFC additionally responded preferentially to happy faces relative to neutral faces. We did not detect preferential responses to angry or fearful faces, or overall differences in response magnitude by emotional valence (100% happy vs. fearful and angry) or intensity (100% vs. 40% fearful and angry). In exploratory analyses, preferential responses to faces in MPFC were not robustly correlated with performance on tasks of early social cognition. These results link and extend adult and infant research on functional responses to faces in STC and MPFC and contribute to the characterization of the neural correlates of early social cognition.     

基于内容分析法的中医类APP现状分析

随着手机APP对人们日常工作和生活方式的改变，中医类APP日益得到关注。文章基于内容分析法对目前中医类APP现状进行梳理，分析存在的问题，对未来中医类APP的设计和开发提出建议。以每一个APP为分析单元，从一般情况、主要功能、用户评价等3个方面进行分析，建立了7个维度22个细目的编码体系，进行频数统计和分析。发现目前中医类APP功能丰富，用户广泛，成为中医药服务及中医科学传播的重要载体，具有良好的用户粘度及巨大市场需求，但存在质量良莠不齐、内容资源不佳等问题。提出中医类APP开发应符合中医药发展战略的方向，应进一步规范中医类APP隐私政策和相关法律法规；并探索中医类APP的评价标准和评价指标体系，促进和规范中医类APP的质量提升和不断发展。     

他山之石 何以攻玉:从脑出血国际临床研究现状看我国的规范化治疗

自发性脑出血病死率和病残率较高,但缺乏有效的治疗策略。我国的脑出血相关研究与国际先进水平存在一定差距。近年国际上一系列临床研究从不同角度探讨脑出血的治疗方式,对我国脑出血研究和规范化治疗具有十分重要的参考价值。我国的脑出血临床治疗经验和研究成果要想走向世界,必须开展高质量的临床试验。四川大学华西医院神经外科正在开展INTERACT3试验,以及准备开展STICHⅢ试验,希望能够推动中国脑出血研究事业的进步。     

Safety and immunogenicity of NVX-CoV2373 (TAK-019) vaccine in healthy Japanese adults: Interim report of a phase I/II randomized controlled trial

BackgroundWe evaluated the safety and immunogenicity of NVX-CoV2373, a recombinant SARS-CoV-2 nanoparticle vaccine, in healthy Japanese participants.MethodsThis phase 1/2, randomized, observer-blind, placebo-controlled trial conducted in Japan (two sites), enrolled healthy Japanese adults aged ≥ 20 years with no history/risk of SARS-CoV-2 infection and no prior exposure to other approved/investigational SARS-CoV-2 vaccines or treatments. Participants were stratified by age (< 65 or ≥ 65 years) and randomized to receive two doses of either NVX-CoV2373 (5 μg SARS-CoV-2 rS; 50 μg Matrix-M1) or placebo, 21 days apart. Primary outcomes were safety and immunogenicity assessed by serum IgG antibody levels against SARS-CoV-2 rS protein on day 36. Herein, we report the primary data analysis at 4 weeks after the second dose, ahead of 12-month follow-up completion (data cut-off: 8 May 2021).ResultsBetween 12 February 2021 and 17 March 2021, 326 subjects were screened, and 200 participants enrolled and randomized: NVX-CoV2373, n = 150; placebo, n = 50. Solicited adverse events (AEs) through 7 days after each injection occurred in 121/150 (80.7%) and 11/50 (22.0%) participants in the NVX-CoV2373 and placebo arms, respectively. In the NVX-CoV2373 arm, tenderness and injection site pain were the most frequently reported solicited AEs after each vaccination, irrespective of age. Robust immune responses occurred with NVX-CoV2373 (n = 150) by day 36: IgG geometric mean fold rise (95% confidence interval) 259 (219, 306); seroconversion rate 100% (97.6, 100). No such response occurred with placebo (n = 49).ConclusionTwo doses of NVX-CoV2373 given with a 21-day interval demonstrated acceptable safety and induced robust anti-SARS-CoV-2 immune responses in healthy Japanese adults. Funding: Takeda Pharmaceutical Company Limited and Japan Agency for Medical Research and Development (AMED). ClinicalTrials.gov identifier: NCT04712110.